Share:
Share this content in WeChat
X
• Review •
Research progress of radiomics and deep learning in efficacy evaluation and prognosis prediction of liver malignant tumors
ZHANG Bingyan  HUA Li  LONG Die  CHEN Shaojun 

DOI:10.12015/issn.1674-8034.2026.11.023.


[Abstract] In recent years, radiomics and deep learning (DL) have experienced rapid development. Radiomics employs high-throughput extraction and analysis of quantitative features within medical images to non-invasively evaluate tumor therapeutic response and predict patient prognosis. DL based on convolutional neural networks further enhances the accuracy and automation of image analysis. Both approaches provide clinical support and new research directions for the systemic and local treatments of malignant liver tumors. Despite demonstrating extensive application prospects, both fields currently face significant challenges. This review systematically summarizes the progress of radiomics and DL across different treatment modalities for liver malignant tumors, clarifies their practical value and applicable scenarios in efficacy prediction and prognosis evaluation, summarizes current limitations in the field, and highlights future directions including multimodal fusion, dynamic prediction models construction, and multicenter large-sample prospective studies. The aim is to advance artificial intelligence-driven precision medicine for liver malignancies.
[Keywords] liver malignancies;systemic therapy;local therapy;radiomics;deep learning;magnetic resonance imaging

ZHANG Bingyan   HUA Li   LONG Die   CHEN Shaojun*  

Oncology Diagnosis and Treatment Center, the Fourth Affiliated Hospital of Guangxi Medical University, Liuzhou 545005, China

Corresponding author: CHEN S J, E-mail: chenshaojunguangxi@126.com

Conflicts of interest   None.

Received  2026-01-10
Accepted  2026-08-24
DOI: 10.12015/issn.1674-8034.2026.11.023
DOI:10.12015/issn.1674-8034.2026.11.023.

[1]
HAN B F, ZHENG R S, ZENG H M, et al. Cancer incidence and mortality in China, 2022[J]. J Natl Cancer Cent, 2024, 4(1): 47-53. DOI: 10.1016/j.jncc.2024.01.006.
[2]
TSILIMIGRAS D I, BRODT P, CLAVIEN P A, et al. Liver metastases[J/OL]. Nat Rev Dis Primers, 2021, 7(1): 27 [2026-01-09]. https://www.nature.com/articles/s41572-021-00261-6. DOI: 10.1038/s41572-021-00261-6.
[3]
IPPOLITO D, INCHINGOLO R, GRAZIOLI L, et al. Recent advances in non-invasive magnetic resonance imaging assessment of hepatocellular carcinoma[J]. World J Gastroenterol, 2018, 24(23): 2413-2426. DOI: 10.3748/wjg.v24.i23.2413.
[4]
WEI J W, JIANG H Y, GU D S, et al. Radiomics in liver diseases: Current progress and future opportunities[J]. Liver Int, 2020, 40(9): 2050-2063. DOI: 10.1111/liv.14555.
[5]
CHU L C, PARK S, KAWAMOTO S, et al. Current status of radiomics and deep learning in liver imaging[J]. J Comput Assist Tomogr, 2021, 45(3): 343-351. DOI: 10.1097/rct.0000000000001169.
[6]
LI M, XU G, CUI Y, et al. CT-based radiomics nomogram for the preoperative prediction of microsatellite instability and clinical outcomes in colorectal cancer: a multicentre study[J/OL]. Clin Radiol, 2023, 78(10): e741-e751 [2026-01-09]. https://pubmed.ncbi.nlm.nih.gov/37487841/. DOI: 10.1016/j.crad.2023.06.012.
[7]
YANG C J, WANG C K, FANG Y D, et al. Clinical application of mask region-based convolutional neural network for the automatic detection and segmentation of abnormal liver density based on hepatocellular carcinoma computed tomography datasets[J/OL]. PLoS One, 2021, 16(8): e0255605 [2026-01-09]. https://pubmed.ncbi.nlm.nih.gov/34375365/. DOI: 10.1371/journal.pone.0255605.
[8]
KIM D W, LEE G, KIM S Y, et al. Deep learning-based algorithm to detect primary hepatic malignancy in multiphase CT of patients at high risk for HCC[J]. Eur Radiol, 2021, 31(9): 7047-7057. DOI: 10.1007/s00330-021-07803-2.
[9]
KUSHNURE D T, TALBAR S N. HFRU-Net: high-level feature fusion and recalibration UNet for automatic liver and tumor segmentation in CT images[J/OL]. Comput Methods Programs Biomed, 2022, 213: 106501 [2026-01-09]. https://pubmed.ncbi.nlm.nih.gov/34752959/. DOI: 10.1016/j.cmpb.2021.106501.
[10]
LI X M, CHEN H, QI X J, et al. H-DenseUNet: hybrid densely connected UNet for liver and tumor segmentation from CT volumes[J]. IEEE Trans Med Imaging, 2018, 37(12): 2663-2674. DOI: 10.1109/TMI.2018.2845918.
[11]
CAO L P, WANG Q, HONG J W, et al. MVI-TR: a transformer-based deep learning model with contrast-enhanced CT for preoperative prediction of microvascular invasion in hepatocellular carcinoma[J/OL]. Cancers, 2023, 15(5): 1538 [2026-01-09]. https://pubmed.ncbi.nlm.nih.gov/36900327/. DOI: 10.3390/cancers15051538.
[12]
WANG L Y, WU M L, LI R, et al. MVI-mind: a novel deep-learning strategy using computed tomography (CT)-based radiomics for end-to-end high efficiency prediction of microvascular invasion in hepatocellular carcinoma[J/OL]. Cancers, 2022, 14(12): 2956 [2026-01-09]. https://pubmed.ncbi.nlm.nih.gov/35740620/. DOI: 10.3390/cancers14122956.
[13]
HAGHSHOMAR M, RODRIGUES D, KALYAN A, et al. Leveraging radiomics and AI for precision diagnosis and prognostication of liver malignancies[J/OL]. Front Oncol, 2024, 14: 1362737 [2026-01-09]. https://pubmed.ncbi.nlm.nih.gov/38779098/. DOI: 10.3389/fonc.2024.1362737.
[14]
LAMBIN P, RIOS-VELAZQUEZ E, LEIJENAAR R, et al. Radiomics: extracting more information from medical images using advanced feature analysis[J]. Eur J Cancer, 2012, 48(4): 441-446. DOI: 10.1016/j.ejca.2011.11.036.
[15]
INCHINGOLO R, MAINO C, CANNELLA R, et al. Radiomics in colorectal cancer patients[J]. World J Gastroenterol, 2023, 29(19): 2888-2904. DOI: 10.3748/wjg.v29.i19.2888.
[16]
LEE J G, JUN S, CHO Y W, et al. Deep learning in medical imaging: general overview[J]. Korean J Radiol, 2017, 18(4): 570-584. DOI: 10.3348/kjr.2017.18.4.570.
[17]
PARK H J, PARK B, LEE S S. Radiomics and deep learning: hepatic applications[J/OL]. Korean J Radiol, 2020, 21(4): 387 [2026-01-09]. https://pubmed.ncbi.nlm.nih.gov/32193887/. DOI: 10.3348/kjr.2019.0752.
[18]
BO Z Y, CHEN B, ZHAO Z X, et al. Prediction of response to lenvatinib monotherapy for unresectable hepatocellular carcinoma by machine learning radiomics: a multicenter cohort study[J]. Clin Cancer Res, 2023, 29(9): 1730-1740. DOI: 10.1158/1078-0432.CCR-22-2784.
[19]
SUN C, WANG Q, HOU L, et al. A contrast-enhanced ultrasound-based nomogram for the prediction of therapeutic efficiency of anti-PD-1 plus anti-VEGF agents in advanced hepatocellular carcinoma patients[J/OL]. Front Immunol, 2023, 14: 1229560 [2026-01-09]. https://pubmed.ncbi.nlm.nih.gov/37575236/. DOI: 10.3389/fimmu.2023.1229560.
[20]
DONG W, JI Y, PI S, et al. Noninvasive imaging-based machine learning algorithm to identify progressive disease in advanced hepatocellular carcinoma receiving second-line systemic therapy[J/OL]. Sci Rep, 2023, 13(1): 10690 [2026-01-09]. https://pubmed.ncbi.nlm.nih.gov/37393336/. DOI: 10.1038/s41598-023-37862-y.
[21]
CUI H, ZENG L, LI R, et al. Radiomics signature based on CECT for non-invasive prediction of response to anti-PD-1 therapy in patients with hepatocellular carcinoma[J/OL]. Clin Radiol, 2023, 78(2): e37-e44 [2026-01-09]. https://pubmed.ncbi.nlm.nih.gov/36257868/. DOI: 10.1016/j.crad.2022.09.113.
[22]
YUAN G S, SONG Y D, LI Q, et al. Development and validation of a contrast-enhanced CT-based radiomics nomogram for prediction of therapeutic efficacy of anti-PD-1 antibodies in advanced HCC patients[J/OL]. Front Immunol, 2020, 11: 613946 [2026-01-09]. https://pubmed.ncbi.nlm.nih.gov/33488622/. DOI: 10.3389/fimmu.2020.613946.
[23]
YU G B, ZHANG Z G, ERESEN A, et al. MRI radiomics to monitor therapeutic outcome of sorafenib plus IHA transcatheter NK cell combination therapy in hepatocellular carcinoma[J/OL]. J Transl Med, 2024, 22(1): 76 [2026-01-09]. https://pubmed.ncbi.nlm.nih.gov/38243292/. DOI: 10.1186/s12967-024-04873-w.
[24]
XU J, WANG T F, LI J J, et al. A multimodal fusion system predicting survival benefits of immune checkpoint inhibitors in unresectable hepatocellular carcinoma[J/OL]. NPJ Precis Oncol, 2025, 9(1): 185 [2026-01-09]. https://pubmed.ncbi.nlm.nih.gov/40517171/. DOI: 10.1038/s41698-025-00979-6.
[25]
WEI N, MATHY R M, CHANG D H, et al. Longitudinal CE-MRI-based Siamese network with machine learning to predict tumor response in HCC after DEB-TACE[J/OL]. Cancer Imaging, 2025, 25(1): 104 [2026-01-09]. https://pubmed.ncbi.nlm.nih.gov/40830494/. DOI: 10.1186/s40644-025-00926-5.
[26]
LIN Z J, WANG W D, YAN Y C, et al. A deep learning-based clinical-radiomics model predicting the treatment response of immune checkpoint inhibitors (ICIs)-based conversion therapy in potentially convertible hepatocelluar carcinoma patients: a tumor marker prognostic study[J]. Int J Surg, 2025, 111(5): 3342-3355. DOI: 10.1097/JS9.0000000000002322.
[27]
TIAN Y C, KOMOLAFE T E, ZHENG J, et al. Assessing PD-L1 expression level via preoperative MRI in HCC based on integrating deep learning and radiomics features[J/OL]. Diagnostics (Basel), 2021, 11(10): 1875 [2026-01-09]. https://pubmed.ncbi.nlm.nih.gov/34679573/. DOI: 10.3390/diagnostics11101875.
[28]
HAN X, PENG C, RUAN S M, et al. A contrast-enhanced ultrasound cine-based deep learning model for predicting the response of advanced hepatocellular carcinoma to hepatic arterial infusion chemotherapy combined with systemic therapies[J]. Cancer Sci, 2025, 116(7): 1930-1940. DOI: 10.1111/cas.70089.
[29]
NARDONE V, PATANÈ V, MARINELLI L, et al. Delta-radiomics biomarker in colorectal cancer liver metastases treated with cetuximab plus avelumab (CAVE trial)[J/OL]. Diagnostics (Basel), 2025, 15(22): 2914 [2026-01-09]. https://pubmed.ncbi.nlm.nih.gov/41300938/. DOI: 10.3390/diagnostics15222914.
[30]
MIYAMOTO Y, NAKAURA T, OHUCHI M, et al. Radiomics-based machine learning approach to predict chemotherapy responses in colorectal liver metastases[J]. J Anus Rectum Colon, 2025, 9(1): 117-126. DOI: 10.23922/jarc.2024-077.
[31]
GIANNINI V, ROSATI S, DEFEUDIS A, et al. Radiomics predicts response of individual HER2-amplified colorectal cancer liver metastases in patients treated with HER2-targeted therapy[J]. Int J Cancer, 2020, 147(11): 3215-3223. DOI: 10.1002/ijc.33271.
[32]
GIANNINI V, PUSCEDDU L, DEFEUDIS A, et al. Delta-radiomics predicts response to first-line oxaliplatin-based chemotherapy in colorectal cancer patients with liver metastases[J/OL]. Cancers, 2022, 14(1): 241 [2026-01-09]. https://pubmed.ncbi.nlm.nih.gov/35008405/. DOI: 10.3390/cancers14010241.
[33]
AMMIRABILE A, LEVI R, BOLDRINI L, et al. MRI-based radiomics predicts the pathologic response of colorectal liver metastases to systemic therapy: A multicenter study[J/OL]. Eur J Radiol, 2025, 191: 112325 [2026-01-09]. https://pubmed.ncbi.nlm.nih.gov/40752452/. DOI: 10.1016/j.ejrad.2025.112325.
[34]
WANG X H, LIU Z Q, YIN X P, et al. A radiomics model fusing clinical features to predict microsatellite status preoperatively in colorectal cancer liver metastasis[J/OL]. BMC Gastroenterol, 2023, 23(1): 308 [2026-01-09]. https://pubmed.ncbi.nlm.nih.gov/37700238/. DOI: 10.1186/s12876-023-02922-0.
[35]
QU H, ZHAI H, ZHANG S R, et al. Dynamic radiomics for predicting the efficacy of antiangiogenic therapy in colorectal liver metastases[J/OL]. Front Oncol, 2023, 13: 992096 [2026-01-09]. https://pubmed.ncbi.nlm.nih.gov/36814812/. DOI: 10.3389/fonc.2023.992096.
[36]
QI W, YANG J, ZHENG L B, et al. CT-based radiomics for the identification of colorectal cancer liver metastases sensitive to first-line irinotecan-based chemotherapy[J]. Med Phys, 2023, 50(5): 2705-2714. DOI: 10.1002/mp.16325.
[37]
WEI J W, CHENG J, GU D S, et al. Deep learning-based radiomics predicts response to chemotherapy in colorectal liver metastases[J]. Med Phys, 2021, 48(1): 513-522. DOI: 10.1002/mp.14563.
[38]
CHIU S H, LI H C, CHANG W C, et al. Improving the prediction of patient survival with the aid of residual convolutional neural network (ResNet) in colorectal cancer with unresectable liver metastases treated with bevacizumab-based chemotherapy[J/OL]. Cancer Imaging, 2024, 24(1): 165 [2026-01-09]. https://pubmed.ncbi.nlm.nih.gov/39696483/. DOI: 10.1186/s40644-024-00809-1.
[39]
ZHOU S Z, SUN D Z, MAO W J, et al. Deep radiomics-based fusion model for prediction of bevacizumab treatment response and outcome in patients with colorectal cancer liver metastases: a multicentre cohort study[J/OL]. EClinicalMedicine, 2023, 65: 102271 [2026-01-09]. https://pubmed.ncbi.nlm.nih.gov/37869523/. DOI: 10.1016/j.eclinm.2023.102271.
[40]
ZHOU J, SUN H C, WANG Z, et al. China liver cancer guidelines for the diagnosis and treatment of hepatocellular carcinoma (2024 edition)[J]. Liver Cancer, 2025, 14(6): 779-835. DOI: 10.1159/000546574.
[41]
SALEM R, JOHNSON G E, KIM E, et al. Yttrium-90 radioembolization for the treatment of solitary, unresectable HCC: the LEGACY study[J]. Hepatology, 2021, 74(5): 2342-2352. DOI: 10.1002/hep.31819.
[42]
LIU J G, ZHANG J J, WANG Y J, et al. HAIC versus TACE for patients with unresectable hepatocellular carcinoma: A systematic review and meta-analysis[J/OL]. Medicine, 2022, 101(51): e32390 [2026-01-09]. https://pubmed.ncbi.nlm.nih.gov/36595819/. DOI: 10.1097/MD.0000000000032390.
[43]
JI G W, ZHU F P, XU Q, et al. Radiomic features at contrast-enhanced CT predict recurrence in early stage hepatocellular carcinoma: a multi-institutional study[J]. Radiology, 2020, 294(3): 568-579. DOI: 10.1148/radiol.2020191470.
[44]
SCHINDLER P, VON BEAUVAIS P, HOFFMANN E, et al. Combining radiomics and imaging biomarkers with clinical variables for the prediction of HCC recurrence after liver transplantation[J]. Liver Transpl, 2025, 31(10): 1226-1237. DOI: 10.1097/LVT.0000000000000603.
[45]
TABARI A, D'AMORE B, COX M, et al. Machine learning-based radiomic features on pre-ablation MRI as predictors of pathologic response in patients with hepatocellular carcinoma who underwent hepatic transplant[J/OL]. Cancers, 2023, 15(7): 2058 [2026-01-09]. https://pubmed.ncbi.nlm.nih.gov/37046718/. DOI: 10.3390/cancers15072058.
[46]
ZHANG X J, WANG C D, ZHENG D, et al. Radiomics nomogram based on multi-parametric magnetic resonance imaging for predicting early recurrence in small hepatocellular carcinoma after radiofrequency ablation[J/OL]. Front Oncol, 2022, 12: 1013770 [2026-01-09]. https://pubmed.ncbi.nlm.nih.gov/36439458/. DOI: 10.3389/fonc.2022.1013770.
[47]
PENG J, LU F Y, HUANG J H, et al. Development and validation of a pyradiomics signature to predict initial treatment response and prognosis during transarterial chemoembolization in hepatocellular carcinoma[J/OL]. Front Oncol, 2022, 12: 853254 [2026-01-09]. https://pubmed.ncbi.nlm.nih.gov/36324581/. DOI: 10.3389/fonc.2022.853254.
[48]
CHEN M Y, CAO J S, HU J H, et al. Clinical-radiomic analysis for pretreatment prediction of objective response to first transarterial chemoembolization in hepatocellular carcinoma[J]. Liver Cancer, 2021, 10(1): 38-51. DOI: 10.1159/000512028.
[49]
ZHAO Y, HUANG F, LIU S Y, et al. Prediction of therapeutic response of unresectable hepatocellular carcinoma to hepatic arterial infusion chemotherapy based on pretherapeutic MRI radiomics and Albumin-Bilirubin score[J]. J Cancer Res Clin Oncol, 2023, 149(8): 5181-5192. DOI: 10.1007/s00432-022-04467-3.
[50]
WEI L S, ARYAL M P, CUNEO K, et al. Deep learning prediction of post-SBRT liver function changes and NTCP modeling in hepatocellular carcinoma based on DGAE-MRI[J]. Med Phys, 2023, 50(9): 5597-5608. DOI: 10.1002/mp.16386.
[51]
XU Z M, AN C, SHI F, et al. Automatic prediction of hepatic arterial infusion chemotherapy response in advanced hepatocellular carcinoma with deep learning radiomic nomogram[J]. Eur Radiol, 2023, 33(12): 9038-9051. DOI: 10.1007/s00330-023-09953-x.
[52]
ZHANG L, JIANG Y C, JIN Z, et al. Real-time automatic prediction of treatment response to transcatheter arterial chemoembolization in patients with hepatocellular carcinoma using deep learning based on digital subtraction angiography videos[J/OL]. Cancer Imaging, 2022, 22(1): 23 [2026-01-09]. https://pubmed.ncbi.nlm.nih.gov/35549776/. DOI: 10.1186/s40644-022-00457-3.
[53]
GAO W Y, WANG W T, SONG D J, et al. A predictive model integrating deep and radiomics features based on gadobenate dimeglumine-enhanced MRI for postoperative early recurrence of hepatocellular carcinoma[J]. Radiol Med, 2022, 127(3): 259-271. DOI: 10.1007/s11547-021-01445-6.
[54]
YAN M, ZHANG X, ZHANG B, et al. Deep learning nomogram based on Gd-EOB-DTPA MRI for predicting early recurrence in hepatocellular carcinoma after hepatectomy[J]. Eur Radiol, 2023, 33(7): 4949-4961. DOI: 10.1007/s00330-023-09419-0.
[55]
CHEN Y, PASQUIER D, VERSTAPPEN D, et al. An interpretable ensemble model combining handcrafted radiomics and deep learning for predicting the overall survival of hepatocellular carcinoma patients after stereotactic body radiation therapy[J/OL]. J Cancer Res Clin Oncol, 2025, 151(2): 84 [2026-01-09]. https://pubmed.ncbi.nlm.nih.gov/39948208/. DOI: 10.1007/s00432-025-06119-8.
[56]
WANG Y D, ZHANG Y, XIAO J C, et al. Multicenter integration of MR radiomics, deep learning, and clinical indicators for predicting hepatocellular carcinoma recurrence after thermal ablation[J]. J Hepatocell Carcinoma, 2024, 11: 1861-1874. DOI: 10.2147/JHC.S482760.
[57]
WU J P, DING W Z, WANG Y L, et al. Radiomics analysis of ultrasound to predict recurrence of hepatocellular carcinoma after microwave ablation[J]. Int J Hyperthermia, 2022, 39(1): 595-604. DOI: 10.1080/02656736.2022.2062463.
[58]
LIU F, LIU D, WANG K, et al. Deep learning radiomics based on contrast-enhanced ultrasound might optimize curative treatments for very-early or early-stage hepatocellular carcinoma patients[J]. Liver Cancer, 2020, 9(4): 397-413. DOI: 10.1159/000505694.
[59]
LIU P, ZHU H T, ZHU H B, et al. Predicting survival for hepatic arterial infusion chemotherapy of unresectable colorectal liver metastases: radiomics analysis of pretreatment computed tomography[J]. J Transl Int Med, 2022, 10(1): 56-64. DOI: 10.2478/jtim-2022-0004.
[60]
SHUR J, ORTON M, CONNOR A, et al. A clinical-radiomic model for improved prognostication of surgical candidates with colorectal liver metastases[J]. J Surg Oncol, 2020, 121(2): 357-364. DOI: 10.1002/jso.25783.
[61]
HU R, CHEN I, PEOPLES J, et al. Radiomics artificial intelligence modelling for prediction of local control for colorectal liver metastases treated with radiotherapy[J]. Phys Imaging Radiat Oncol, 2022, 24: 36-42. DOI: 10.1016/j.phro.2022.09.004.
[62]
SHAHVERANOVA A, BALLI H T, AIKIMBAEV K, et al. Prediction of local tumor progression after microwave ablation in colorectal carcinoma liver metastases patients by MRI radiomics and clinical characteristics-based combined model: preliminary results[J]. CardioVascular Interv Radiol, 2023, 46(6): 713-725. DOI: 10.1007/s00270-023-03454-6.
[63]
TAGHAVI M, STAAL F, GOMEZ MUNOZ F, et al. CT-based radiomics analysis before thermal ablation to predict local tumor progression for colorectal liver metastases[J]. Cardiovasc Intervent Radiol, 2021, 44(6): 913-920. DOI: 10.1007/s00270-020-02735-8.
[64]
TANG L Z, ZHANG Z T, YANG J Z, et al. A new automated prognostic prediction method based on multi-sequence magnetic resonance imaging for hepatic resection of colorectal cancer liver metastases[J]. IEEE J Biomed Health Inform, 2024, 28(3): 1528-1539. DOI: 10.1109/JBHI.2024.3350247.
[65]
STARMANS M P A, BUISMAN F E, RENCKENS M, et al. Distinguishing pure histopathological growth patterns of colorectal liver metastases on CT using deep learning and radiomics: a pilot study[J]. Clin Exp Metastasis, 2021, 38(5): 483-494. DOI: 10.1007/s10585-021-10119-6.
[66]
GRANATA V, FUSCO R, DE MUZIO F, et al. Contrast MR-based radiomics and machine learning analysis to assess clinical outcomes following liver resection in colorectal liver metastases: a preliminary study[J/OL]. Cancers, 2022, 14(5): 1110 [2026-01-09]. https://pubmed.ncbi.nlm.nih.gov/35267418/. DOI: 10.3390/cancers14051110.
[67]
ZHAO Q X, HE X L, WANG K, et al. Deep learning model based on contrast-enhanced ultrasound for predicting early recurrence after thermal ablation of colorectal cancer liver metastasis[J]. Eur Radiol, 2023, 33(3): 1895-1905. DOI: 10.1007/s00330-022-09203-6.
[68]
KOBE A, ZGRAGGEN J, MESSMER F, et al. Prediction of treatment response to transarterial radioembolization of liver metastases: Radiomics analysis of pre-treatment cone-beam CT: A proof of concept study[J/OL]. Eur J Radiol Open, 2021, 8: 100375 [2026-01-09]. https://pubmed.ncbi.nlm.nih.gov/34485629/. DOI: 10.1016/j.ejro.2021.100375.

PREV Research progress of CT and MRI radiomics in predicting postoperative recurrence of hepatocellular carcinoma
NEXT Research progress of radiomics in predicting treatment response and prognosis of hepatocellular carcinoma after TACE
  



Tel & Fax: +8610-67113815    E-mail: editor@cjmri.cn